For Veeva, the consensus sales estimate for the current quarter of $727.99 million indicates a year-over-year change of +11.9%. For the current and next fiscal years, $3.05 billion and $3.42 ...

Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial Veeva ...

Veeva Systems is overvalued, trading at frothy levels despite only ~10% growth, and facing a potential slowdown in 2025; I recommend a sell rating. The company excels in the life sciences vertical ...

In conversation with Fierce Pharma, Anthony Billinger, senior director of Compass Strategy at Veeva Systems, sheds light on the rapidly evolving world of commercial data in life sciences—and why ...

Yet, this upbeat vision is being undercut by another cornerstone of Trump's economic ... 3 Medical Info Systems Stocks to Bet On Veeva Systems offers cloud-based software applications and data ...